Introduction
EpCAM-targeted immunotherapy for treatment of gastrointestinal malignancies provided controversial results
, the recent phase I trial of adecatumumab, a fully human anti-EpCAM antibody, in patients with hormone refractory prostate cancer has proven that medication is well tolerated. Adecatumumab is currently undergoing phase II trial in prostate and breast cancer patients [16, 17] .
Bispecific antibodies (bsAb), which were used in our present study, are artificial molecules with dual specificity to two different antigens. They represent a new class of immunotherapeutic agents [18, 19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Quadroma-derived bsAb showed promising results in phase I/II trials [27, 30] . However, a relatively short half-life of recombinant bsAb constructs, overt production of cytokines, Fc-mediated side effects and bsAb immunogenicity limit their clinical application [19] . To [31, 32] . [31, 34] . Parental anti-human EpCAM hybridoma (HEA125; IgG1) was raised in our laboratory [35, 36] . Hybridoma OKT3 (IgG2A) directed against the ⑀-chain of the CD3 molecule was purchased from the ATCC. Both parental mAbs were purified by affinity chromatography.
. One of the concepts behind the use of bsAb in anticancer immunotherapy is their ability to bind to tumour-associated antigens with one arm and to specific molecules on immune cells with the other arm. This brings tumour and immune cells in close contact, triggers immune cell activation and redirects immune cells to kill tumour cells

. The most commonly used antigen for bsAb on lymphocytes is an invariant CD3 signalling complex, which induces a polyclonal T-cell activation. Several bsAb and single-chain antibody constructs against EpCAM expressed by tumour cells have been generated and tested as immunotherapeutic agents
overcome some of these obstacles, we developed mouse bsAb composed of mouse IgG1 and IgG2A constant heavy-chain regions, which has low affinity to human Fc receptors, to target human EpCAM on carcinoma cells and CD3 antigen on lymphocytes. This reagent, EpCAMxCD3 (HEA125xOKT3), efficiently induced tumour cell lysis in vitro, and an intraperitoneal application of bsAb reduced malignant ascites production in advanced ovarian cancer patients
In the present study, we investigated the anti-tumour efficiency of EpCAMxCD3 in pancreatic cancer. To begin with, we established an in vitro three-dimensional (3D) tumour reconstruct system, which closely resembles the microenvironment of pancreatic tumours. EpCAMxCD3 potently inhibited subcutaneous tumour engraftment (tumour take) and retarded growth of BxPC-3 pancreatic xenografts in NOD SCID mice. In collagen gel 3D tumour reconstructs, EpCAMxCD3 markedly increased the contact time between lymphocytes and carcinoma cells. Furthermore, EpCAMxCD3 induced production of effector cytokines TNF-␣ and IFN-␥ more efficiently than a bivalent anti-CD3 antibody. Here, we show for the first time that increasing the contact time between CD3-positive lymphocytes and EpCAM-expressing tumour cells is a key event for EpCAMxCD3 anti-cancer efficiency.
Material and methods
Primary and established cell lines
In vitro collagen gel 3D tumour reconstruct system
To create 3D tumour reconstructs and to mimic tumour microenvironment, BxPC-3 cells, lymphocytes and fibroblasts were cultured in a collagen type I gel on chamber slides (Nunc, Rochester, NY). The collagen type I gel was prepared as described previously [37] . Briefly (Fig. 6A ). The TGF-␤1 level ranged from 50 to 100 pg/ml (Fig. 6B) . [28, 30, 39, 40] . A single-chain bsAb EpCAMxCD3, MT102, reduced growth of experimental SW480 colon tumours [28] . Because the terminal elimination half-life of MT102 is around 5.3 hrs, it had to be administered daily [28] . Importantly, we have found that our bsAb EpCAMxCD3 has a much longer half-life in mouse serum (t1/2~ 7 days) and was detectable in tumours even 7 days after the last administration. [31] . By 
injections of either control parental bivalent anti-human EpCAM and anti-CD3 mAbs at a dose of 1 mg/kg (A), EpCAMxCD3 at doses 10 mg/kg (B), 1 mg/kg (C), 0.1 mg/kg (D) or PBS (E). Treatment was repeated four times with a 3-day interval. Tumour growth
3B). Also perforin level was increased in 3D reconstructs with EpCAMxCD3 after 24 hrs of incubation compared with irrelevant CD19xCD3 bsAb. There was no difference in perforin levels between all groups after 72 hrs (Suppl. Fig. 3B). Similarly, a loading of nonstimulated PBMCs with EpCAMxCD3 for 2 hrs prior to 3D tumour reconstruct experiments resulted in an increased production of IFN-␥ and TNF-␣ compared with an addition of EpCAMxCD3. Thus, in 24 hrs the level of IFN-␥ increased by 45% and after 72 hrs of incubation by 70%. In 24 hrs the production of TNF-␣ increased by 20%, compared with about 8 times increase in TNF-␣ production in 72 hrs following incubation (data not shown). In contrast to 3D tumour reconstructs with pre-activated lymphocytes, EpCAMxCD3 induced production of the inhibitory cytokine IL-10 in 3D tumour reconstructs with non-stimulated PBMCs
Because monocyte-derived IL-1␤ can induce the TGF-␤ production by fibroblasts, we analyzed its concentration in 3D tumour reconstructs. The amount of IL-1␤ was around 300 pg/ml in all 3D tumour reconstructs and EpCAMxCD3 did not influence IL-1␤ production. Concentrations of IL-10, IL-1␤ and TGF-␤1 were not detectable in 3D tumour reconstructs of carcinoma cells co-cultured with fibroblasts without PBMCs. Taken together, we clearly demonstrate that EpCAMxCD3 potently stimulates pre-activated lymphocytes and non-stimulated PBMCs to secrete effector cytokines in 3D tumour reconstructs in the presence of EpCAM-expressing carcinoma cells.
Discussion
In the present work, we provide evidence that bsAb EpCAMxCD3 reduced tumour take and efficiently inhibited growth of experimental © 2009 The Authors Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 5 Effects of EpCAMxCD3 on the production of effector cytokines by non-stimulated PBMCs in 3D tumour reconstructs. The ability of EpCAMxCD3 to induce the production of IFN-␥ (A), TNF-␣ (B) and IL-2 (C) by non-stimulated PBMCs was analyzed in 3D tumour
Therefore, an increased serum half-life of EpCAMxCD3 may provide a considerable clinical advantage over single-chain bsAb constructs. In addition, attempts to generate recombinant humanized EpCAMxCD3 constructs are underway in our laboratories (Deppe et al., in preparation). Previously, we have shown that EpCAMxCD3 brings T cells and tumour cells in a close contact redirecting T cells to kill carcinoma cells
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Fig. S1. Anti-tumor efficiency of EpCAMxCD3 in in vivo
